secwatch.observer — SEC 8-K summary
======================================

Issuer:     MERIT MEDICAL SYSTEMS INC (MMSI)
CIK:        0000856982
Form:       8-K
Filed at:   2025-05-20T23:59:59+00:00
Accession:  0000856982-25-000035
Event type: m_and_a
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01, 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Merit Medical acquires Biolife for $120M in cash; adds StatSeal/WoundSeal hemostasis products
--------------------------------------------------------------------------------

- Purchase price $120M cash; Biolife becomes wholly-owned subsidiary of Merit.
- Biolife's revenue projected at ~$18M annualized starting FY 2026 with mid-teens growth.
- StatSeal/WoundSeal products address ~$350M global hemostasis market.
- Merit reaffirms FY 2025 guidance; acquisition slightly dilutive to 2025 non-GAAP profitability.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/856982/000085698225000035/0000856982-25-000035-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/856982/000085698225000035/mmsi-20250516x8k.htm
  HTML page:      https://secwatch.observer/filing/0000856982-25-000035

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer